NASDAQ:RMTI Rockwell Medical Q3 2025 Earnings Report $1.18 -0.02 (-1.26%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Rockwell Medical EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/ARockwell Medical Revenue ResultsActual RevenueN/AExpected Revenue$16.24 millionBeat/MissN/AYoY Revenue GrowthN/ARockwell Medical Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Rockwell Medical Earnings HeadlinesHead-To-Head Comparison: Rockwell Medical (NASDAQ:RMTI) & ICU Medical (NASDAQ:ICUI)October 16 at 2:09 AM | americanbankingnews.comRockwell Medical to Release Third Quarter 2025 Results on Wednesday, November 12, 2025October 15 at 7:01 AM | businesswire.comYou’ve Got to See This Pattern Before 2025 Picks Up…After analyzing 30 days of small-cap movement, we uncovered a repeating signal that keeps flashing before certain tickers break out — and it’s appearing again as we move deeper into 2025. Our free Small-Cap Signal Blueprint shows exactly what to look for so you can recognize the next move before it happens.October 17 at 2:00 AM | Stock Wire News (Ad)Short Interest in Rockwell Medical, Inc. (NASDAQ:RMTI) Rises By 52.0%October 9, 2025 | americanbankingnews.comRockwell Medical promotes Heather Hunter to COOSeptember 30, 2025 | seekingalpha.comRockwell Medical Promotes Heather Hunter to Chief Operating OfficerSeptember 30, 2025 | businesswire.comSee More Rockwell Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rockwell Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rockwell Medical and other key companies, straight to your email. Email Address About Rockwell MedicalRockwell Medical (NASDAQ:RMTI) is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings. The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients. TRIFERIC is delivered via dialysate and is intended to replace iron losses that occur during the dialysis process, helping to maintain hemoglobin levels without the need for intravenous iron supplements. In addition to TRIFERIC, Rockwell Medical offers a generic injectable formulation of calcitriol, a form of vitamin D used to manage secondary hyperparathyroidism in CKD patients. Since its founding in 1991, Rockwell Medical has conducted research, clinical development, and regulatory activities primarily in the United States. The company collaborates with specialty distributors and dialysis providers to commercialize its products and is exploring further innovations, including oral formulations of its iron therapy. Rockwell Medical’s operations are led by an experienced management team with backgrounds in nephrology, pharmaceutical development, and health-care commercialization, reflecting its commitment to improving patient outcomes in the CKD community.View Rockwell Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Nasdaq (10/21/2025)PACCAR (10/21/2025)Texas Instruments (10/21/2025)Intuitive Surgical (10/21/2025)Netflix (10/21/2025)Verizon Communications (10/21/2025)General Motors (10/21/2025)CocaCola (10/21/2025)Citigroup (10/21/2025)3M (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
